Healthcare
Live Price
Offline$16.41
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars · Jun 23, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Welcia Holdings Co., Ltd. (WLCGF) is a Healthcare stock with a market cap of $3.42B and listed on OTC. The stock last traded around $16.41 and up 0.0% across the available one-year price window (Jun 23, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +5.6%, EPS growth of -43.5%, a dividend yield of 0.6%. What stands out right now is revenue +5.6%, EPS -43.5%, free cash flow +25.5% with operating margin 3.0% and ROIC 6.7%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 34.3 and price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WLCGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WLCGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WLCGF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WLCGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$949.7B
-7.4% YoY
FY Net Income
$28.0B
+5.8% YoY
Free Cash Flow
$31.9B
+913.6% YoY
Revenue Growth
+5.6%
EPS Growth
-43.5%
Gross Margin
30.3%
Net Margin
1.4%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1285.0B | 1217.3B | 1144.3B | 1025.9B | 949.7B |
| Gross Profit | 390.4B | 370.1B | 326.3B | 302.3B | 279.4B |
| Operating Income | 36.4B | 43.2B | 45.6B | 43.0B | 43.0B |
| EBITDA | 53.3B | 65.4B | 68.9B | 62.0B | 60.0B |
| Net Income | 15.0B | 26.5B | 27.0B | 26.5B | 28.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.0B | 30.5B | 32.3B | 22.8B | 50.9B |
| Total Assets | 580.0B | 551.9B | 537.4B | 463.0B | 435.7B |
| Total Liabilities | 325.5B | 307.5B | 305.0B | 255.2B | 255.3B |
| Shareholder Equity | 248.6B | 237.7B | 225.9B | 201.8B | 179.7B |
| Total Debt | 81.2B | 82.7B | 86.1B | 62.5B | 47.7B |
| Net Debt | 46.2B | 52.2B | 53.8B | 39.7B | -3.2B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
46.4B
+185.9% YoY
Capital Expenditures
14.5B
+28.2% YoY
Free Cash Flow
31.9B
+913.6% YoY
Key ratios
Gross Margin
30.3%
Operating Margin
3.0%
Net Margin
1.4%
ROE
7.6%
Debt / Equity
0.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.